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Abstract
Background: Febrile neutropaenia (FN) is a very common complication in patients with haematological
malignancies and is associated with considerable morbidity and mortality. Broad-spectrum antipseudomonal β-
lactam antibiotics (BLA) are routinely used for the treatment of cancer patients with FN. However, the clinical
efficacy of BLA may be diminished in these patients because they present with pathophysiological variations that
compromise the pharmacokinetic (PK) parameters of these antibiotics. Optimised administration of BLA in
prolonged infusions has demonstrated better clinical outcomes in critically ill patients. However, there is a paucity
of data on the usefulness of this strategy in patients with FN.
The aim of this study is to test the hypothesis that the administration of BLA would be clinically more effective by
extended infusion (EI) than by intermittent infusion (II) in haematological patients with FN.
Methods: A randomised, multicentre, open-label, superiority clinical trial will be performed. Patients with haematological
malignancies undergoing chemotherapy or haematopoietic stem-cell transplant and who have FN and receive empirical
antibiotic therapy with cefepime, piperacillin-tazobactam or meropenem will be randomised (1:1) to receive the antibiotic
by EI (during half the time of the dosing interval) in the study group, or by II (30min) in the control group.
The primary endpoint will be clinical efficacy, defined as defervescence without modifying the antibiotic treatment
administered within the first 5 days of therapy. The primary endpoint will be analysed in the intention-to-treat population.
The secondary endpoints will be pharmacokinetic/pharmacodynamic (PK/PD) target achievement, bacteraemia clearance,
decrease in C-reactive protein, overall (30-day) case-fatality rate, adverse events and development of a population PK
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model of the BLA studied.
Discussion: Data on the usefulness of BLA administration in patients with FN are scant. Only three clinical studies
addressing this issue have been published thus far, with contradictory results. Moreover, these studies had some
methodological flaws that limit the interpretation of their findings. If this randomised, multicentre, phase IV, open-label,
superiority clinical trial validates the hypothesis that the administration of BLA is clinically more effective by EI than by II in
haematological patients with FN, then the daily routine management of these high-risk patients could be changed to
improve their outcomes.
Trial registration: European Clinical Trials Database: EudraCT 2018–001476-37.
ClinicalTrials.gov, ID: NCT04233996.
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Background
Febrile neutropaenia (FN) is a very common complica-
tion in patients with haematological diseases and is asso-
ciated with considerable morbidity and mortality.
Neutropaenia increases the susceptibility of patients to
infections, which are more frequent and more severe de-
pending on the degree and duration of the neutropaenia.
However, only 30% of patients with FN develop a clinic-
ally or microbiologically documented infection, and only
20% develop bacteraemia. The epidemiology of bacter-
aemia in cancer patients has changed in recent decades,
with an increase in Gram-negative bacilli, and more im-
portantly, an emergence of multidrug antibiotic resist-
ance among these organisms [1, 2]. This is of particular
concern because adequate empirical antibiotic treatment
is associated with increased survival rates in patients
with FN [3].
β-lactam antibiotics (BLA) are the most widely used
antibiotics in the routine management of FN. Therefore,
optimising the use of BLA is essential to improve the
prognosis of these patients. One way to optimise the use
of these drugs is to administer them by extended infu-
sion (EI) or continuous infusion (CI). This approach al-
lows free (unbound) concentrations of the drug to be
maintained above the minimum inhibitory concentration
(MIC) of the pathogen during the dosing interval (fT >
MIC) [4, 5]. Studies seem to show improved outcomes
in terms of microbiological eradication, clinical success
and mortality when critically ill patients achieve this
pharmacokinetic/pharmacodynamic (PK/PD) target [6–
9]. Moreover, two recent meta-analyses have shown an
association between prolonged infusion of BLA and
lower mortality rates [10, 11]. Similar results have also
been observed in a non-randomised prospective study in
cirrhotic patients with bloodstream infections, in whom
prolonged infusion of BLA was associated with improved
survival [12]. Nevertheless, earlier studies addressing this
issue have mainly focussed on the general non-severely
immunocompromised population.
Patients with FN are similar to critically ill patients in
terms of the intra- and inter-individual variability of PK
parameters, mainly due to an increased volume of distri-
bution and an increased renal clearance [13–15]. BLA
PK parameters are widely affected by these pathophysio-
logical changes. In fact, it has been suggested that in pa-
tients with FN, some BLA administered by II may not
achieve desirable PK/PD parameters [16–18]. Moreover,
the PK/PD therapeutic target is still uncertain in neutro-
paenic patients, and further studies are required to valid-
ate the magnitude of the optimal PK/PD index.
Regarding the clinical impact of optimised BLA, data
on neutropaenic patients are limited and restricted to
certain antibiotics. A prospective, randomised pilot study
that analysed cefepime administered by EI and II found
no significant clinical differences between the two strat-
egies [19]. However, it should be noted that septic pa-
tients were excluded from the analysis, despite being the
subgroup that would most benefit from EI. A retrospect-
ive study with 164 patients found clinical efficacy with
the use of meropenem by EI compared to II [20]. Simi-
larly, a recent single-centre, randomised clinical trial
found that EI was associated with superior treatment
outcomes compared with II, and the benefit was greatest
for patients with pneumonia [21]. Nevertheless, the
study had some methodological flaws, and no PK studies
were performed to support the clinical results [22].
In the current era of widespread antimicrobial resist-
ance, and due to the lack of new antibiotics, the use of
optimised administration of BLA may play an important
role in the management of infections in cancer patients.
For instance, it may prevent the emergence of resistance
[23] and may be a better approach for treating hard-to-
treat infections [24].
This randomised clinical trial aims to test the hypoth-
esis that the administration of BLA would be clinically
more effective by EI than by II in haematological pa-
tients with FN. Patients with FN may benefit from the
clinical impact of this strategy, reducing the duration of
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fever, the global antibiotic consumption and mortality
rates. A PK/PD study will also be performed to assess
the correlation with the clinical results.
Hypothesis
The administration of BLA by EI would be clinically
more effective than by II in haematological patients with
FN.
In haematological patients with FN, the administration
of BLA by EI would be superior to II in reaching the
PK/PD target, clearing up bacteraemia more quickly and
decreasing inflammatory biomarkers. Both strategies
would be equally safe.
Trial design
The BEATLE study is a phase IV, randomised, multicen-
tre, open-label, superiority clinical trial to determine the
clinical superiority of EI versus II administration of BLA
used as empirical treatment in patients with FN. The
BLA studied will be cefepime, piperacillin-tazobactam
and meropenem. Patients will be randomised (1:1) at FN
onset to receive BLA by EI or II. The intervention will
last 5 days.
The manuscript has been prepared in accordance with
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) [25], Additional file 1.




The study will be conducted in four university hospitals in
Spain. The reference site will be Institut Català d’Oncologia
L’Hospitalet (ICO Hospitalet) – Hospital Universitari Bell-
vitge. The other three participating sites will be Hospital
Clinic de Barcelona (Barcelona), Hospital Germans Trias i
Pujol (Barcelona) and Clínica Universidad de Navarra
(Pamplona).
Study population and screening of cases for recruitment
This study will include adult patients with haemato-
logical malignancies admitted to the haematology wards
who are undergoing chemotherapy or haematopoietic
stem-cell transplant (HSCT) and experience FN; partici-
pants will receive empirical antibiotic therapy with one
of the BLA studied.
Inclusion criteria
Adult patients (age ≥ 18 years) undergoing chemotherapy
or HSCT who present with FN (defined as axillary
temperature ≥ 38.0 °C and < 500 neutrophils/mm3 or <
1000 expected to drop within 24–48 h), and who receive
empirical antibiotic therapy with cefepime, piperacillin-
tazobactam or meropenem, in monotherapy or in com-
bination with another antibiotic.
Exclusion criteria
1. Allergy to the study drugs
2. Patient receiving systemic antibiotic treatment
(except for prophylaxis) at the time of FN onset
3. Absence of fever
4. Patients with epilepsy
5. Severe renal impairment (defined as creatinine
clearance rate by MDRD/CKD-EPI < 30 mL/min)
6. Previously enrolled patients in whom the time
between inclusion and the current episode is less
than 5 weeks
7. Previously enrolled patients without current
resolution of the first episode
Intervention
Patients admitted in the haematology wards of the
participating centres, receiving chemotherapy or
HSCT will be followed up daily by the attending phy-
sicians. The study investigators will explain the study
to the patients who meet the inclusion criteria, and
will ask them to sign the informed consent. At the
FN onset, patients will be randomised to receive EI
or II (1:1). The BLA will be chosen according to the
clinical criteria of the attending physician. Once ran-
domised, the first BLA dose will be administered
within 30 min in all patients. The second dose will be
administered according to the randomisation group.
In the control group (II) the BLA will be adminis-
tered within 30 min at the usual doses recommended
for neutropaenic patients (cefepime 2 g/8 h,
piperacillin-tazobactam 4 g/6 h and meropenem 1 g/8
h), adjusted according to renal function (Table 1). In
the study group, the BLA will be administered at the
same doses but by EI (the infusion time will be equal
to half the time of the dosing interval). Episodes of
FN will be classified as ‘microbiologically documented
infection’ (with or without bacteraemia), ‘clinically
documented infection’ (without microbiological isola-
tion), ‘fever of unknown origin’ or ‘non-infectious
fever’.
Patients will remain in the study until completing a
total of 5 days of antibiotic treatment, or until one of the
following events occur: discontinuation of BLA based on
clinical criteria, severe adverse event (SAE) or death. If
any microorganism is isolated, in vitro susceptibility tests
will be performed and antibiotic treatment will be tar-
geted accordingly. If the BLA needs to be switched to
another BLA also included in the study due to a lack of
in vitro activity, the patient will remain in the study.
Measurements and visits will start along with the
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initiation of the second BLA. If the targeted therapy is
an antibiotic not included in the study, the patient will
be withdrawn from the study. All patients will receive
follow-up for 30 days after initiation of the antibiotic
treatment.
The determination of plasma BLA concentrations will
not influence the dosage, indication or duration of the
BLA administered during the study in any case.
The participant timeline during the study is described
in Table 2.
Discontinuation criteria
1) Withdrawal of consent
2) Non-compliance with the inclusion or exclusion
criteria
3) Serious adverse reaction
4) Protocol violation
In accordance with the current revision of the Declar-
ation of Helsinki and the applicable regulations, a patient
has the right to withdraw from the study at any time
and for any reason, without this adversely affecting the
medical care provided by the patient’s physician. The
withdrawal of full consent from a study means that the
patient does not wish to continue participating in the
study. Any patient withdrawing their consent will be re-
moved from the study treatment and/or observations
immediately after the date the patient requests it.
Outcome measures
Primary endpoint
The primary study endpoint is clinical efficacy, measured
by the time to defervescence and no need for antibiotic
Table 1 β-lactam antibiotic adjustment in renal impairment
β-lactam antibiotic Creatinine clearance
(mL/min)
Dose Frequency
Piperacillin-tazobactam 30-40 4 g/0.5 g Every 8 hours
Cefepime 30-50 2 g Every 12 hours
Meropenem 30-50 1 g Every 12 hours
Table 2 Participant timeline of the study
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change. To assess this endpoint the rate of patients with
defervescence with no change to the antibiotic treatment
within the first 5 days of therapy will be calculated. De-
fervescence will be considered to be an axillary
temperature < 37.5 °C for 24 h, assessed at three consecu-
tive time points, with no new documented fever. For this
purpose, axillary temperature will be assessed three
times daily by the attending nurse. Time (in hours) to
defervescence will also be analysed. In addition, pre-
scribed antibiotics will be reviewed every day and re-
corded in the Electronic Case Report Form (E-CRF) by
the participating investigators at each site to estimate
the number of patients who will not require an antibiotic
change.
The primary endpoint will be analysed by an investiga-
tor who will be blind to the treatment group of each
patient.
Secondary endpoints
Secondary endpoints will be assessed as follows:
1. PK targets: number of patients in whom the free-
antibiotic concentration remains above the MIC
of the suspected or isolated microorganism for
50%, 75% and 100% of the dosing interval. The
same target will also be assessed, taking into ac-
count the number of times per patient. Actual
MIC values will be used to assess the PK target in
those patients with an isolated pathogen. Other-
wise, a surrogate MIC will be inferred from the
EUCAST database as the highest MIC in the sus-
ceptible range for Pseudomonas aeruginosa [26].
For this purpose, the nurse in charge of each pa-
tient will take blood samples to determine plasma
BLA concentrations at 50 and 100% of the dosing
interval at visits 1, 2 and 3, and at 75% of the dos-
ing interval at visit 2. The samples will be frozen
and subsequently analysed in the biochemistry la-
boratory at the reference site
2. Bacteraemia clearance: time in days until
bacteraemia clearance. In patients with bacteraemia,
daily blood cultures will be performed by the nurse
in charge of each patient until bacteraemia
clearance
3. Inflammatory biomarkers: time in days to normalise
or decrease > 50% the peak value of C-reactive pro-
tein (CRP), and the number of patients who achieve
this objective. Blood samples for CRP determination
will be drawn at visits 0, 1, 2, 3 and 5, and will be
analysed at each site
4. Overall (30-day) case-fatality rate: all patients in-
cluded in the study will receive follow-up for 30
days after the end of the intervention by the
participating investigators. Death by any cause will
be recorded in the E-CRF
5. Population PK analysis to characterise cefepime,
piperacillin-tazobactam and meropenem PKs in
haematological patients with FN: a population PK
model will be developed and validated, using
concentration-time data obtained from the blood
samples of patients at the reference site (ICO
Hospitalet). For each antibiotic, a simultaneous
analysis of all concentration-time data will be
performed by the population approach using the
non-linear mixed-effect models implemented in
NONMEM 7.4 (Icon development). The model
will allow us to identify the clinical covariables
that modify the PK parameters. Monte-Carlo
simulations will be performed to determine the
suitability of different dosing regimens assessed
by the probability of target attainment. The valid-
ation cohort will include data obtained from pa-
tients at the other sites
6. Adverse events (AEs): all AEs considered not
related to the haematological disease or its
treatment and all SAEs will be recorded in the
E-CRF by the participating investigators. AEs will
be identified and classified according to the se-
verity and potential relationship with the BLA
and assessed during the intervention (until visit
5). Afterwards, any AEs related to BLA adminis-
tration and any SAEs until visit 6 (30 days from
the beginning of the intervention) will be
recorded
Data collection and management
All data will be collected by the clinical investigators at
each participating site and entered in the E-CRF. The
collected data will be age, sex, height, weight, type of
underlying disease, other comorbidities, date of hospital
admission and discharge, HSCT, type and date of HSCT,
immunosuppressive therapy, concomitant medication
(particularly other systemic antibiotics, prophylactic an-
timicrobials, fluids, antipyretics and granulocyte-colony
stimulating factor), duration of neutropaenia, vital signs,
duration of fever, clinical examination, blood tests and
microbiological results.
Microbiological studies
Blood cultures will be drawn at the onset of fever. In pa-
tients with bacteraemia, daily blood cultures will be
taken until clearance. Other cultures will be collected ac-
cording to the usual practice and clinical criteria.
Cultures will be processed in the microbiology la-
boratories at each participating site according to the
usual techniques (BACTEC Becton Dickinson, Bio-
Merieux, etc.). The microorganisms isolated will be
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identified according to the usual methods (conven-
tional method, MALDI-TOF, etc.). Antibiotic suscep-
tibility will be studied by the disc-diffusion method
and/or by microdilution method. In addition, the
exact MIC of the antibiotics administered will be de-
termined by a quantitative method, using E-test and/
or adequate microdilution plates.
Sample collection for PK/PD analysis
Plasma BLA concentrations will be determined seven
times. At visit 1 (which should be performed between
12 and 36 h from the start of the study antibiotic
treatment), the concentrations will be analysed pre-
dose (through concentrations or Cmin) and then mid-
way through the dosing interval (C50). Subsequently,
the Cmin, C50 and the concentration at the 75% of the
dosing interval (C75) will be analysed at visit 2 (if not
possible, this will be done at visit 3 or 4). Last, Cmin
and C50 will be analysed at visit 3 (or if not possible,
at visit 4 or 5, consecutive to the visit-2 samples).
At the reference site, intensive sampling will be carried
out at visit 2. The schedule according to drug, method
of administration and frequency is explained in Tables 3
and 4.
A 5-mL blood sample will be centrifuged at 2000 g for
10 min at 4 °C, and the supernatant will be aliquoted in
1.5-mL microcentrifuge tubes and and stored at − 80 °C
until analysis. Samples will be sent in dry ice to Bellvitge
University Hospital for bioanalysis.
Total plasma BLA concentrations will be analysed
using a previously validated method based on ultra-
high-performance liquid chromatography coupled to
tandem mass spectrometry [27]. Protein binding of
30%, 19% and 2% will be applied for piperacillin, cefe-
pime and meropenem, respectively, to the concentra-
tions determined to estimate the unbound fraction
[28, 29].
Randomisation
Enrolled patients who sign the informed consent will
be randomised to receive BLA by either EI or II (1:1).
A centralised electronic computer randomisation
schedule will be developed by the Biostatistics Depart-
ment of the reference site. To ensure that an equal
number of participants is assigned to each treatment,
patients will be randomised in blocks. The randomisa-
tion will be performed in computed-generated vari-
able blocks ranging from four to six, and the
investigator will be blind to the size of each block.
The code numbers for eligible patients will be
assigned in ascending sequential order. The allocation
list will be stored at the Biostatistics Department of
the reference site. At each participating hospital, pa-
tients who provide written informed consent and
meet the study criteria will be randomised by investi-
gators, who will obtain the assigned treatment and
code number from the computer-assisted web site.
Sample size
The sample size calculation is based on determining
whether the administration of BLA by EI (study group)
will be clinically more effective than the administration
of BLA by II (control group), for the treatment of FN in
haematological patients. Previous data suggest that the
clinical efficacy rate in the control group is expected to
be 0.45 [20, 21]. A relevant clinical efficacy rate in the
study group is expected to be 0.70. Each therapy group
will required 75 participants (total of 150) to detect sta-
tistically significant differences in clinical efficacy. An
alpha risk of 0.05 and a beta risk of 0.2 in a bilateral con-
trast are assumed, and the sample size allows up to 20%
losses to follow-up.
Interim analysis
An interim analysis will be carried out once 50% of the
cases of each arm are recruited. This analysis will evalu-
ate if the estimated sample size is adequate. The results
will be issued by an independent committee of experts
not participating in this study.
Statistical analysis
For the primary endpoint, an intention-to-treat analysis
will be carried out. The number of patients in both ther-
apy groups with defervescence and with no change in
the antibiotic treatment will be compared by a chi-
square test.
For the analysis of secondary endpoints, the between-
group difference in the percentage of patients reaching the
Table 3 Sampling time in the study group (β-lactam antibiotic administration by extended infusion (EI)) according to the frequency
of administration. Time expressed in minutes from the start of drug administration
Frequency of administration Cmin Cmax (C50) Cmax + 30 Cmax + 60 C75
EI 6h -10 180 210 240 270
8h -10 240 270 300 360
12h -10 360 390 420 540
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PK target will be compared. The secondary endpoints are:
(a) days until bacteraemia clearance, (b) time until nor-
malisation or 50% decrease of the initial value of the CRP,
and (c) days until death by any cause within 30 days, and
the incidence of these events will be estimated in each
group. Survival analysis methods will be used to compare
them using the log-rank test. In addition, the rate of thera-
peutic failure will be compared.
A population PK model will be developed and validated
for each BLA studied in haematological patients with FN,
using the concentration-time data obtained from the
blood samples. The model will allow us to identify the
clinical covariates that modify the PK parameters. Monte-
Carlo simulations will be performed to determine the suit-
ability of different dosing regimens assessed by the prob-
ability of target attainment.
The AEs and SAEs of the study will be described, and
their rates will be compared for each group. The severity,
relationship to treatment and resolution will be described.
An analysis by protocol will also be carried out. All
study variables will be presented for each group, using
descriptive statistics according to the type of variable.
The main analysis will be replicated in the following
subgroups: patients with ‘microbiologically documented
infection’ (with and without bacteraemia), ‘clinically doc-
umented infection’, ‘fever of unknown origin’ or ‘non-in-
fectious fever’.
Whenever possible, the estimators of a 95% confidence
interval will be included. Statistical significance will be
set at a probability level < 0.05. The statistical package
used to process the data and carry out the analyses will
be R, version 3.6.1 or higher for Windows.
Monitoring
In compliance with the standards of Good Clinical Prac-
tice, the sponsor will monitor the study tasks, following
the approved monitoring plan. Among others, the moni-
toring tasks will include assessment of the correct appli-
cation of the inclusion and exclusion criteria, assessment
of the quality of the data collected, development and
reporting of any AEs, and maintenance of patient
confidentiality.
The need for a Data Monitoring Committee was
waived by the Ethic Committee because of the low im-
pact on the safety of the study patients.
Discussion
Prolonged infusion of BLA is a simple strategy that has
proven to improve survival among certain populations,
such as critically ill and cirrhotic patients. Broad-
spectrum antipseudomonal BLAs are routinely used to
treat cancer patients with FN. Optimised use of these
antibiotics could improve the outcomes of these pa-
tients, who would benefit from faster defervescence and
microbiological eradication, as well as a decrease in
overall antibiotic exposure. However, there are few data
on the usefulness of this strategy in this high-risk
population.
Only three published clinical studies have addressed
this issue so far, with contradictory results. A prospect-
ive, randomised pilot study compared cefepime adminis-
tration by II to 33 neutropaenic patients with
administration by EI to 30 patients. No significant differ-
ences were found in the primary endpoint of deferves-
cence at 72 h or in the secondary endpoints, such as
clinical success, in-patient mortality, length of hospital
stay or need for additional antibiotics. Although not sta-
tistically significant, defervescence seemed to be faster in
patients treated with cefepime by EI [19]. The main limi-
tation of this study was the exclusion of patients pre-
senting with sepsis. The presence of sepsis in
neutropaenic patients is common and contributes sig-
nificantly to the pathophysiological changes that com-
promise the PK/PD parameters of the BLA and its
efficacy. Therefore, patients with FN and sepsis are
probably the patients who could most benefit from this
administration strategy.
A Spanish group compared the clinical efficacy of mer-
openem by EI versus II in a retrospective observational
study involving haematological patients with FN. Data
Table 4 Sampling time in the control group (β-lactam antibiotic administration by intermittent infusion (II)) according to the
frequency of administration. Time expressed in minutes from the start of drug administration
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on defervescence, resolution or improvement of signs
and symptoms of infection, absence of breakthrough
bacteraemia, and absence of additional antibiotics were
analysed [20]. The administration of meropenem by EI
was found to be clinically more effective, and also
achieved defervescence and a significant decrease of
CRP more rapidly. The limitations of this study were its
retrospective nature, the definition of a combined pri-
mary endpoint using a large number of variables and the
lack of plasma meropenem determinations.
Last, a recent randomised clinical trial reported better
clinical outcomes in patients receiving BLA by EI com-
pared with II, particularly those with pneumonia [21].
Nevertheless, this study had some limitations. First, it
was a single-centre study, which may limit extrapolation
of the results. Second, the definition used for ‘pneumo-
nia’ was somewhat imprecise, as it included all patients
with inflammatory radiological opacities. This is rele-
vant, because pneumonia is the second most common
infection reported in this trial. Third, piperacillin-
tazobactam was used in > 90% of patients. Therefore, the
results should be only interpreted with the use of this
antibiotic. Last, no PK/PD determinations were per-
formed to support the study’s findings.
If our randomised, multicentre, phase IV, open-label,
superiority clinical trial validates the hypothesis that the
administration of BLA by EI is clinically more effective
than by II in haematological patients with FN, then this
could change the daily routine management of these
high-risk patients and, thus, improve their outcomes.
Trial status
The current protocol is version 3.2, dated 9 January
2020. Patient recruitment started on 12 November 2019
and will be completed by November 2021.
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